Journal of the International Neuropsychological Society
July 1, 2021
Kelly A. Sagar, M. Dahlgren, Ashley M. Lambros et al.
Abstract Objective: Cannabis use has increased dramatically across the country; however, few studies have assessed the long-term impact of medical cannabis (MC) use on cognition. Studies examining recreational cannabis users generally report cognitive decrements, particularly in those with adolescent onset. As MC patients differ from recreational consumers in motives for use, product selection,...
JMIR Research Protocols
June 16, 2021
H. Mansell, D. Quinn, L. Kelly et al.
Background Despite the lack of evidence on the use of cannabis for the treatment of attention-deficit/hyperactivity disorder (ADHD), the growing perception that cannabis is safe has led more patients and caregivers to self-medicate. Some psychiatrists now authorize medicinal cannabis for patients with ADHD with features of oppositional defiant disorder (ODD) to curtail the unregulated (ie,...
Translational Psychiatry
April 13, 2021
Lani Cupo, Eric Plitman, Elisa Guma et al.
AbstractAcute exposure to cannabis has been associated with an array of cognitive alterations, increased risk for neuropsychiatric illness, and other neuropsychiatric sequelae including the emergence of acute psychotic symptoms. However, the brain alterations associating cannabis use and these behavioral and clinical phenotypes remains disputed. To this end, neuroimaging can be a powerful...
PLoS One
March 17, 2021
Marcel O Bonn-Miller, Sue Sisley, Paula Riggs et al.
129 citations
IMPORTANCE: There is a pressing need for development of novel pharmacology for the treatment of Posttraumatic Stress Disorder (PTSD). Given increasing use of medical cannabis among US military veterans to self-treat PTSD, there is strong public interest in whether cannabis may be a safe and effective treatment for PTSD. OBJECTIVE: The aim of the present study was to collect preliminary data on...
Frontiers in Psychiatry
February 16, 2021
Maryam Sorkhou, Rachel H. Bedder, T. George
Background: Cannabis is known to have a broad range of effects on behavior, including experiencing a “high” and tranquility/relaxation. However, there are several adverse behavioral sequalae that can arise from cannabis use, depending on frequency of use, potency (e.g., THC content), age of onset, and cumulative exposure. This systematic review examined evidence for cannabis-related adverse...
Journal of Affective Disorders
January 15, 2021
Dakota Mauzay, Emily M LaFrance, Carrie Cuttler
Little is known about the the acute effects of cannabis on symptoms of OCD in humans. Therefore, this study sought to: 1) examine whether symptoms of OCD are significantly reduced after inhaling cannabis, 2) examine predictors (gender, dose, cannabis constituents, time) of these symptom changes and 3) explore potential long-term consequences of repeatedly using cannabis to self-medicate for OCD...
Advances in experimental medicine and biology
2021
Rafael G. Dos Santos, Jaime E. C. Hallak, José Alexandre S. Crippa
Cannabis can synthetize more than 400 compounds, including terpenes, flavonoids, and more than 100 phytocannabinoids. The main phytocannabinoids are Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabis-based products are used as medicines in several countries. In this text, we present an overview of the main neurochemical mechanisms of action of the phytocannabinoids, especially THC...
December 11, 2020
Balázs Szigeti, Laura Kärtner, Allan Blemings et al.
1 citation
Psychedelic psychotherapy, therapy enhanced with psychedelic drugs such as LSD or psilocybin (the active ingredient of ‘magic mushrooms’), has been suggested to improve psychological well-being. For this reason, trials on psychedelic therapy for the treatment of depression, addiction and other conditions are ongoing. Recently, ‘microdosing’ – a way of administering psychedelics that involves...
December 1, 2020
Caroline Mathon, Christèle Widmer, R. Mégevand et al.
Objectif Depuis de nombreuses annees, la politique en matiere de drogues est basee en Suisse sur quatre piliers, a savoir la prevention, la therapie, la repression et la reduction des risques. Parmi les actions mises en œuvre concernant la reduction des risques lies aux consommations recreatives de substances psychoactives, une nouvelle offre a ete proposee depuis 2019 a Geneve, consistant en...
November 27, 2020
Giordano Novak Rossi
A ayahuasca é uma bebida psicoativa tradicionalmente utilizada por grupos indígenas da Amazônia com fins rituais e terapêuticos. Estudos em animais e humanos sugerem que a ayahuasca possui efeitos ansiolíticos e antidepressivos. O canabidiol (CBD) por sua vez é um fitocanabinoide produzido pela planta da maconha, e tem demonstrado diversas aplicações terapêuticas nos últimos anos, incluindo...